Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases

Progress in Neurobiology

Volumn 97, Issue 2, 2012, Pages 152-172

  Sambataro, Fabio ^a   Pennuto, Maria ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Adipose tissue; Glia; Neurons; Pancreas; Polyglutamine diseases; Skeletal and heart muscle; Spermatogenesis

Indexed keywords

3 NITROPROPIONIC ACID; ANDROGEN RECEPTOR; ATAXIN 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CREATINE KINASE; DUTASTERIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIBENCLAMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HUNTINGTIN; LEUPRORELIN; MAMMALIAN TARGET OF RAPAMYCIN; MYOGENIC FACTOR 5; MYOGENIN; NEUROTROPHIN 3; NOTCH RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; POLYGLUTAMINE; ROSIGLITAZONE; SOMATOMEDIN C; TESTOSTERONE; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR PAX7; TRANSCRIPTION FACTOR SOX8; TRANSCRIPTION FACTOR SOX9; VASCULOTROPIN;

ADIPOSE TISSUE; BRAIN NERVE CELL; CELL AUTONOMOUS TOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CORPUS STRIATUM; CYTOTOXICITY; EXCITOTOXICITY; EXOCYTOSIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GERM CELL; GLIA CELL; HEART MUSCLE; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KENNEDY DISEASE; MOTONEURON; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPATHOLOGY; NON CELL AUTONOMOUS TOXICITY; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SKELETAL MUSCLE; SKELETAL MUSCLE SATELLITE CELL; SPERMATOGENESIS; SPINOCEREBELLAR DEGENERATION; TRIGEMINAL NUCLEUS;

ADIPOSE TISSUE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MUSCLE, SKELETAL; NEURODEGENERATIVE DISEASES; NEURONS; PANCREAS; PEPTIDES; SPERMATOGENESIS;

EID: 84860664590     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.10.003     Document Type: Review

References (310)

1. Al-Shamma H.A., Arnold A.P. Brain-derived neurotrophic factor regulates expression of androgen receptors in perineal motoneurons. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1521-1526.
2. Amato A.A., Prior T.W., Barohn R.J., Snyder P., Papp A., Mendell J.R. Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology 1993, 43:791-794.
3. Andreassen O.A., Dedeoglu A., Stanojevic V., Hughes D.B., Browne S.E., Leech C.A., Ferrante R.J., Habener J.F., Beal M.F., Thomas M.K. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol. Dis. 2002, 11:410-424.
4. Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., Adam S., Starr E., Squitieri F., Lin B., Kalchman M.A., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 1993, 4:398-403.
5. Araki I., Harada Y., Kuno M. Target-dependent hormonal control of neuron size in the rat spinal nucleus of the bulbocavernosus. J. Neurosci. 1991, 11:3025-3033.
6. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
7. Aylward E.H., Liu D., Nopoulos P.C., Ross C.A., Pierson R.K., Mills J.A., Long J.D., Paulsen J.S. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol. Psychiatry 2011, Sep 8. [Epub ahead of print].
8. Aziz N.A., van der Burg J.M., Landwehrmeyer G.B., Brundin P., Stijnen T., Roos R.A. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008, 71:1506-1513.
9. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429:413-417.
10. Bacos K., Bjorkqvist M., Petersen A., Luts L., Maat-Schieman M.L., Roos R.A., Sundler F., Brundin P., Mulder H., Wierup N. Islet beta-cell area and hormone expression are unaltered in Huntington's disease. Histochem. Cell Biol. 2008, 129:623-629.
11. Banno H., Katsuno M., Suzuki K., Takeuchi Y., Kawashima M., Suga N., Takamori M., Ito M., Nakamura T., Matsuo K., Yamada S., Oki Y., Adachi H., Minamiyama M., Waza M., Atsuta N., Watanabe H., Fujimoto Y., Nakashima T., Tanaka F., Doyu M., Sobue G. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann. Neurol. 2009, 65:140-150.
12. Battaglia F., Le Galudec V., Cossee M., Tranchant C., Warter J.M., Echaniz-Laguna A. Kennedy's disease initially manifesting as an endocrine disorder. J. Clin. Neuromuscul. Dis. 2003, 4:165-167.
13. Baumgartner B.J., Shine H.D. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. J. Neurosci. 1997, 17:6504-6511.
14. Bergmann M., Volpel M., Kuchelmeister K. Onuf's nucleus is frequently involved in motor neuron disease/amyotrophic lateral sclerosis. J. Neurol. Sci. 1995, 129:141-146.
15. Bhasin S., Storer T.W., Berman N., Yarasheski K.E., Clevenger B., Phillips J., Lee W.P., Bunnell T.J., Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J. Clin. Endocrinol. Metab. 1997, 82:407-413.
16. Bichelmeier U., Schmidt T., Hubener J., Boy J., Ruttiger L., Habig K., Poths S., Bonin M., Knipper M., Schmidt W.J., Wilbertz J., Wolburg H., Laccone F., Riess O. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J. Neurosci. 2007, 27:7418-7428.
17. Bjorkqvist M., Fex M., Renstrom E., Wierup N., Petersen A., Gil J., Bacos K., Popovic N., Li J.Y., Sundler F., Brundin P., Mulder H. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum. Mol. Genet. 2005, 14:565-574.
18. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001, 3:1014-1019.
19. Bodner R.A., Outeiro T.F., Altmann S., Maxwell M.M., Cho S.H., Hyman B.T., McLean P.J., Young A.B., Housman D.E., Kazantsev A.G. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4246-4251.
20. Boesgaard T.W., Nielsen T.T., Josefsen K., Hansen T., Jorgensen T., Pedersen O., Norremolle A., Nielsen J.E., Hasholt L. Huntington's disease does not appear to increase the risk of diabetes mellitus. J. Neuroendocrinol. 2009, 21:770-776.
21. Bogaert E., Van Damme P., Van Den Bosch L., Robberecht W. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve 2006, 34:391-405.
22. Bohanna I., Georgiou-Karistianis N., Hannan A.J., Egan G.F. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res. Rev. 2008, 58:209-225.
23. Bohnen N.I., Koeppe R.A., Meyer P., Ficaro E., Wernette K., Kilbourn M.R., Kuhl D.E., Frey K.A., Albin R.L. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000, 54:1753-1759.
24. Bradford J., Shin J.Y., Roberts M., Wang C.E., Li X.J., Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:22480-22485.
25. Breedlove S.M., Arnold A.P. Hormone accumulation in a sexually dimorphic motor nucleus of the rat spinal cord. Science 1980, 210:564-566.
26. Breedlove S.M., Arnold A.P. Sexually dimorphic motor nucleus in the rat lumbar spinal cord: response to adult hormone manipulation, absence in androgen-insensitive rats. Brain Res. 1981, 225:297-307.
27. Brodsky I.G., Balagopal P., Nair K.S. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81:3469-3475.
28. Brooks B.P., Merry D.E., Paulson H.L., Lieberman A.P., Kolson D.L., Fischbeck K.H. A cell culture model for androgen effects in motor neurons. J. Neurochem. 1998, 70:1054-1060.
29. Brooks B.P., Paulson H.L., Merry D.E., Salazar-Grueso E.F., Brinkmann A.O., Wilson E.M., Fischbeck K.H. Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol. Dis. 1997, 3:313-323.
30. Brown D., Hikim A.P., Kovacheva E.L., Sinha-Hikim I. Mouse model of testosterone-induced muscle fiber hypertrophy: involvement of p38 mitogen-activated protein kinase-mediated Notch signaling. J. Endocrinol. 2009, 201:129-139.
31. Brown T.B., Bogush A.I., Ehrlich M.E. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum. Mol. Genet. 2008, 17:3095-3104.
32. Burnett B., Li F., Pittman R.N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 2003, 12:3195-3205.
33. Burright E.N., Clark H.B., Servadio A., Matilla T., Feddersen R.M., Yunis W.S., Duvick L.A., Zoghbi H.Y., Orr H.T. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 1995, 82:937-948.
34. Busse M.E., Hughes G., Wiles C.M., Rosser A.E. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease. J. Neurol. 2008, 255:1534-1540.
35. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 2004, 84:277-359.
36. Caroni P., Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J. Cell Biol. 1990, 110:1307-1317.
37. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19:3248-3257.
38. Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma×spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 1992, 194:209-221.
39. Chahin N., Sorenson E.J. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve 2009, 40:126-129.
40. Chang C., Chen Y.T., Yeh S.D., Xu Q., Wang R.S., Guillou F., Lardy H., Yeh S. Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6876-6881.
41. Chaturvedi R.K., Adhihetty P., Shukla S., Hennessy T., Calingasan N., Yang L., Starkov A., Kiaei M., Cannella M., Sassone J., Ciammola A., Squitieri F., Beal M.F. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 2009, 18:3048-3065.
42. Chen C.M. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med. J. 2011, 34:135-152.
43. Chevalier-Larsen E.S., Merry D.E. Testosterone treatment fails to accelerate disease in a transgenic mouse model of spinal and bulbar muscular atrophy. Dis. Model. Mech. 2011, Oct 4. [Epub ahead of print].
44. Chevalier-Larsen E.S., O'Brien C.J., Wang H., Jenkins S.C., Holder L., Lieberman A.P., Merry D.E. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci. 2004, 24:4778-4786.
45. Chvatal A., Anderova M., Neprasova H., Prajerova I., Benesova J., Butenko O., Verkhratsky A. Pathological potential of astroglia. Physiol. Res. 2008, 57(Suppl. 3):S101-S110.
46. Ciammola A., Sassone J., Alberti L., Meola G., Mancinelli E., Russo M.A., Squitieri F., Silani V. Increased apoptosis Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ. 2006, 13:2068-2078.
47. Ciammola A., Sassone J., Sciacco M., Mencacci N.E., Ripolone M., Bizzi C., Colciago C., Moggio M., Parati G., Silani V., Malfatto G. Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease. Mov. Disord. 2011, 26:130-137.
48. Coleman M.E., DeMayo F., Yin K.C., Lee H.M., Geske R., Montgomery C., Schwartz R.J. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 1995, 270:12109-12116.
49. Conboy I.M., Conboy M.J., Smythe G.M., Rando T.A. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003, 302:1575-1577.
50. Coyle J.T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263:244-246.
51. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
52. Custer S.K., Garden G.A., Gill N., Rueb U., Libby R.T., Schultz C., Guyenet S.J., Deller T., Westrum L.E., Sopher B.L., La Spada A.R. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat. Neurosci. 2006, 9:1302-1311.
53. Cypess A.M., Kahn C.R. The role and importance of brown adipose tissue in energy homeostasis. Curr. Opin. Pediatr. 2010, 22:478-484.
54. David G., Abbas N., Stevanin G., Durr A., Yvert G., Cancel G., Weber C., Imbert G., Saudou F., Antoniou E., Drabkin H., Gemmill R., Giunti P., Benomar A., Wood N., Ruberg M., Agid Y., Mandel J.L., Brice A. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat. Genet. 1997, 17:65-70.
55. de Almeida L.P., Ross C.A., Zala D., Aebischer P., Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 2002, 22:3473-3483.
56. De Gendt K., Swinnen J.V., Saunders P.T., Schoonjans L., Dewerchin M., Devos A., Tan K., Atanassova N., Claessens F., Lecureuil C., Heyns W., Carmeliet P., Guillou F., Sharpe R.M., Verhoeven G. A sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1327-1332.
57. Dejager S., Bry-Gauillard H., Bruckert E., Eymard B., Salachas F., LeGuern E., Tardieu S., Chadarevian R., Giral P., Turpin G. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J. Clin. Endocrinol. Metab. 2002, 87:3893-3901.
58. Dewhurst K., Oliver J.E., McKnight A.L. Socio-psychiatric consequences of Huntington's disease. Br. J. Psychiatry 1970, 116:255-258.
59. Diel P., Baadners D., Schlupmann K., Velders M., Schwarz J.P. C2C12 myoblastoma cell differentiation and proliferation is stimulated by androgens and associated with a modulation of myostatin and Pax7 expression. J. Mol. Endocrinol. 2008, 40:231-241.
60. DiStefano P.S., Friedman B., Radziejewski C., Alexander C., Boland P., Schick C.M., Lindsay R.M., Wiegand S.J. The neurotrophins BDNF NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 1992, 8:983-993.
61. Djousse L., Knowlton B., Cupples L.A., Marder K., Shoulson I., Myers R.H. Weight loss in early stage of Huntington's disease. Neurology 2002, 59:1325-1330.
62. DonCarlos L.L., Garcia-Ovejero D., Sarkey S., Garcia-Segura L.M., Azcoitia I. Androgen receptor immunoreactivity in forebrain axons and dendrites in the rat. Endocrinology 2003, 144:3632-3638.
63. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 2000, 26:300-306.
64. Dube J.Y., Lesage R., Tremblay R.R. Androgen and estrogen binding in rat skeletal and perineal muscles. Can. J. Biochem. 1976, 54:50-55.
65. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
66. Eddy E.M. Male germ cell gene expression. Recent Prog. Horm. Res. 2002, 57:103-128.
67. Evert B.O., Vogt I.R., Vieira-Saecker A.M., Ozimek L., de Vos R.A., Brunt E.R., Klockgether T., Wullner U. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J. Neuropathol. Exp. Neurol. 2003, 62:1006-1018.
68. Fain J.N., Del Mar N.A., Meade C.A., Reiner A., Goldowitz D. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum. Mol. Genet. 2001, 10:145-152.
69. Farrer L.A. Diabetes mellitus in Huntington disease. Clin. Genet. 1985, 27:62-67.
70. Fernandez-Rhodes L.E., Kokkinis A.D., White M.J., Watts C.A., Auh S., Jeffries N.O., Shrader J.A., Lehky T.J., Li L., Ryder J.E., Levy E.W., Solomon B.I., Harris-Love M.O., La Pean A., Schindler A.B., Chen C., Di Prospero N.A., Fischbeck K.H. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011, 10:140-147.
71. Ferrante R.J., Gutekunst C.A., Persichetti F., McNeil S.M., Kowall N.W., Gusella J.F., MacDonald M.E., Beal M.F., Hersch S.M. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 1997, 17:3052-3063.
72. Ferrante R.J., Kowall N.W. Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum. Brain Res. 1987, 416:141-146.
73. Fishman R.B., Breedlove S.M. Local perineal implants of anti-androgen block masculinization of the spinal nucleus of the bulbocavernosus. Brain Res. Dev. Brain Res. 1992, 70:283-286.
74. Fishman R.B., Chism L., Firestone G.L., Breedlove S.M. Evidence for androgen receptors in sexually dimorphic perineal muscles of neonatal male rats absence of androgen accumulation by the perineal motoneurons. J. Neurobiol. 1990, 21:694-704.
75. Folstein S., Abbott M.H., Chase G.A., Jensen B.A., Folstein M.F. The association of affective disorder with Huntington's disease in a case series and in families. Psychol. Med. 1983, 13:537-542.
76. Forger N.G., Roberts S.L., Wong V., Breedlove S.M. Ciliary neurotrophic factor maintains motoneurons and their target muscles in developing rats. J. Neurosci. 1993, 13:4720-4726.
77. Friedman M.J., Shah A.G., Fang Z.H., Ward E.G., Warren S.T., Li S., Li X.J. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat. Neurosci. 2007, 10:1519-1528.
78. Funakoshi H., Frisen J., Barbany G., Timmusk T., Zachrisson O., Verge V.M., Persson H. Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. J. Cell Biol. 1993, 123:455-465.
79. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., Coffman J.A., Surmeier D.J., Honig M.G., Carlock L.R., Reiner A. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 1999, 19:1189-1202.
80. Garden G.A., Libby R.T., Fu Y.H., Kinoshita Y., Huang J., Possin D.E., Smith A.C., Martinez R.A., Fine G.C., Grote S.K., Ware C.B., Einum D.D., Morrison R.S., Ptacek L.J., Sopher B.L., La Spada A.R. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J. Neurosci. 2002, 22:4897-4905.
81. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
82. Gil J.M., Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 2008, 27:2803-2820.
83. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S., Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997, 120(Pt 3):503-514.
84. Glass D., Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann. N. Y. Acad. Sci. 2010, 1211:25-36.
85. Godin J.D., Colombo K., Molina-Calavita M., Keryer G., Zala D., Charrin B.C., Dietrich P., Volvert M.L., Guillemot F., Dragatsis I., Bellaiche Y., Saudou F., Nguyen L., Humbert S. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
86. Goldenberg J.N., Bradley W.G. Testosterone therapy and the pathogenesis of Kennedy's disease (X-linked bulbospinal muscular atrophy). J. Neurol. Sci. 1996, 135:158-161.
87. Goodman A.O., Murgatroyd P.R., Medina-Gomez G., Wood N.I., Finer N., Vidal-Puig A.J., Morton A.J., Barker R.A. The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study. Exp. Neurol. 2008, 210:691-698.
88. Gravel C., Gotz R., Lorrain A., Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat. Med. 1997, 3:765-770.
89. Gu X., Andre V.M., Cepeda C., Li S.H., Li X.J., Levine M.S., Yang X.W. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2007, 2:8.
90. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., Iwasato T., Itohara S., Li X.J., Mody I., Heintz N., Yang X.W. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
91. Guidetti D., Vescovini E., Motti L., Ghidoni E., Gemignani F., Marbini A., Patrosso M.C., Ferlini A., Solime F. X-linked bulbar and spinal muscular atrophy, or Kennedy disease: clinical, neurophysiological, neuropathological, neuropsychological and molecular study of a large family. J. Neurol. Sci. 1996, 135:140-148.
92. Guyot M.C., Hantraye P., Dolan R., Palfi S., Maziere M., Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997, 79:45-56.
93. Haase G., Kennel P., Pettmann B., Vigne E., Akli S., Revah F., Schmalbruch H., Kahn A. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat. Med. 1997, 3:429-436.
94. Haase G., Pettmann B., Vigne E., Castelnau-Ptakhine L., Schmalbruch H., Kahn A. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action. J. Neurol. Sci. 1998, 160(Suppl. 1):S97-S105.
95. Hackam A.S., Hodgson J.G., Singaraja R., Zhang T., Gan L., Gutekunst C.A., Hersch S.M., Hayden M.R. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:1047-1055.
96. Han I., You Y., Kordower J.H., Brady S.T., Morfini G.A. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J. Neurochem. 2010, 113:1073-1091.
97. Hansson O., Petersen A., Leist M., Nicotera P., Castilho R.F., Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8727-8732.
98. Harding A.E., Thomas P.K., Baraitser M., Bradbury P.G., Morgan-Hughes J.A., Ponsford J.R. X-linked recessive bulbospinal neuronopathy: a report of ten cases. J. Neurol. Neurosurg. Psychiatry 1982, 45:1012-1019.
99. Hartgens F., Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004, 34:513-554.
100. Hauser K.F., MacLusky N.J., Toran-Allerand C.D. Androgen action in fetal mouse spinal cord cultures: metabolic and morphologic aspects. Brain Res. 1987, 406:62-72.
101. Hauser K.F., Toran-Allerand C.D. Androgen increases the number of cells in fetal mouse spinal cord cultures: implications for motoneuron survival. Brain Res. 1989, 485:157-164.
102. Helmlinger D., Hardy S., Sasorith S., Klein F., Robert F., Weber C., Miguet L., Potier N., Van-Dorsselaer A., Wurtz J.M., Mandel J.L., Tora L., Devys D. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum. Mol. Genet. 2004, 13:1257-1265.
103. Henderson C.E., Phillips H.S., Pollock R.A., Davies A.M., Lemeulle C., Armanini M., Simmons L., Moffet B., Vandlen R.A., Simpson L.C., et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994, 266:1062-1064.
104. Ho Kim S., Thomas C.A., Andre V.M., Cummings D.M., Cepeda C., Levine M.S., Ehrlich M.E. Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro 2011, 3:e00060. 10.1042/AN20110009.
105. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
106. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
107. Houenou L.J., Oppenheim R.W., Li L., Lo A.C., Prevette D. Regulation of spinal motoneuron survival by GDNF during development and following injury. Cell Tissue Res. 1996, 286:219-223.
108. Hughes R.A., Sendtner M., Thoenen H. Members of several gene families influence survival of rat motoneurons in vitro and in vivo. J. Neurosci. Res. 1993, 36:663-671.
109. Hunt M.J., Morton A.J. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp. Brain Res. 2005, 166:220-229.
110. Huot P., Levesque M., Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007, 130:222-232.
111. Hurlbert M.S., Zhou W., Wasmeier C., Kaddis F.G., Hutton J.C., Freed C.R. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 1999, 48:649-651.
112. Ikeda K., Klinkosz B., Greene T., Cedarbaum J.M., Wong V., Lindsay R.M., Mitsumoto H. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. 1995, 37:505-511.
113. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
114. Imbert G., Saudou F., Yvert G., Devys D., Trottier Y., Garnier J.M., Weber C., Mandel J.L., Cancel G., Abbas N., Durr A., Didierjean O., Stevanin G., Agid Y., Brice A. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 1996, 14:285-291.
115. Javaherian A., Cline H.T. Coordinated motor neuron axon growth and neuromuscular synaptogenesis are promoted by CPG15 in vivo. Neuron 2005, 45:505-512.
116. Jin Y.N., Johnson G.V. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J. Bioenerg. Biomembr. 2010, 42:199-205.
117. Johansen J.A., Breedlove S.M., Jordan C.L. Androgen receptor expression in the levator ani muscle of male mice. J. Neuroendocrinol. 2007, 19:823-826.
118. Johansen J.A., Troxell-Smith S.M., Yu Z., Mo K., Monks D.A., Lieberman A.P., Breedlove S.M., Jordan C.L. Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy. Neurodegener. Dis. 2011, 8:25-34.
119. Johansen J.A., Yu Z., Mo K., Monks D.A., Lieberman A.P., Breedlove S.M., Jordan C.L. Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy. Neurobiol. Dis. 2009, 34:113-120.
120. Jordan C.L., Breedlove S.M., Arnold A.P. Sexual dimorphism and the influence of neonatal androgen in the dorsolateral motor nucleus of the rat lumbar spinal cord. Brain Res. 1982, 249:309-314.
121. Josefsen K., Nielsen M.D., Jorgensen K.H., Bock T., Norremolle A., Sorensen S.A., Naver B., Hasholt L. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J. Neuroendocrinol. 2008, 20:165-172.
122. Kadi F., Charifi N., Denis C., Lexell J. Satellite cells and myonuclei in young and elderly women and men. Muscle Nerve 2004, 29:120-127.
123. Kadi F., Eriksson A., Holmner S., Thornell L.E. Effects of anabolic steroids on the muscle cells of strength-trained athletes. Med. Sci. Sports Exerc. 1999, 31:1528-1534.
124. Kang J.S., Krauss R.S. Muscle stem cells in developmental and regenerative myogenesis. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:243-248.
125. Kassubek J., Gaus W., Landwehrmeyer G.B. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2004, 62:523-524. (author reply 524).
126. Katsuno M., Adachi H., Doyu M., Minamiyama M., Sang C., Kobayashi Y., Inukai A., Sobue G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 2003, 9:768-773.
127. Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002, 35:843-854.
128. Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M., Katayama S., Kawakami H., Nakamura S., Nishimura M., Akiguchi I., et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 1994, 8:221-228.
129. Kemp M.Q., Poort J.L., Baqri R.M., Lieberman A.P., Breedlove S.M., Miller K.E., Jordan C.L. Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action. Hum. Mol. Genet. 2011, 20:4475-4490.
130. Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968, 18:671-680.
131. Kerr J.E., Allore R.J., Beck S.G., Handa R.J. Distribution and hormonal regulation of androgen receptor (AR) and AR messenger ribonucleic acid in the rat hippocampus. Endocrinology 1995, 136:3213-3221.
132. Kihira T., Yoshida S., Yoshimasu F., Wakayama I., Yase Y. Involvement of Onuf's nucleus in amyotrophic lateral sclerosis. J. Neurol. Sci. 1997, 147:81-88.
133. Kimura N., Mizokami A., Oonuma T., Sasano H., Nagura H. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J. Histochem. Cytochem. 1993, 41:671-678.
134. Kinirons P., Rouleau G.A. Administration of testosterone results in reversible deterioration in Kennedy's disease. J. Neurol. Neurosurg. Psychiatry 2008, 79:106-107.
135. Kishino A., Ishige Y., Tatsuno T., Nakayama C., Noguchi H. BDNF prevents and reverses adult rat motor neuron degeneration and induces axonal outgrowth. Exp. Neurol. 1997, 144:273-286.
136. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53.
137. Knight S.P., Richardson M.M., Osmand A.P., Stakkestad A., Potter N.T. Expression and distribution of the dentatorubral-pallidoluysian atrophy gene product (atrophin-1/drplap) in neuronal and non-neuronal tissues. J. Neurol. Sci. 1997, 146:19-26.
138. Kovacheva E.L., Hikim A.P., Shen R., Sinha I., Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 2010, 151:628-638.
139. Kremer H.P., Roos R.A. Weight loss in Huntington's disease. Arch. Neurol. 1992, 49:349.
140. Kremer H.P., Roos R.A., Dingjan G., Marani E., Bots G.T. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J. Neuropathol. Exp. Neurol. 1990, 49:371-382.
141. Kremer H.P., Roos R.A., Dingjan G.M., Bots G.T., Bruyn G.W., Hofman M.A. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci. Lett. 1991, 132:101-104.
142. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
143. Lalic N.M., Dragasevic N., Stefanova E., Jotic A., Lalic K., Milicic T., Petrovic I., Macesic M., Kostic V.S. Impaired insulin sensitivity and secretion in normoglycemic patients with spinocerebellar ataxia type 1. Mov. Disord. 2010, 25:1976-1980.
144. Lalic N.M., Maric J., Svetel M., Jotic A., Stefanova E., Lalic K., Dragasevic N., Milicic T., Lukic L., Kostic V.S. Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch. Neurol. 2008, 65:476-480.
145. Lambrechts D., Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim. Biophys. Acta 2006, 1762:1109-1121.
146. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 2003, 34:383-394.
147. Lee D.K. Androgen receptor enhances myogenin expression and accelerates differentiation. Biochem. Biophys. Res. Commun. 2002, 294:408-413.
148. Li S.H., Schilling G., Young W.S., Li X.J., Margolis R.L., Stine O.C., Wagster M.V., Abbott M.H., Franz M.L., Ranen N.G., et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993, 11:985-993.
149. Li X.J., Li S.H., Sharp A.H., Nucifora F.C., Schilling G., Lanahan A., Worley P., Snyder S.H., Ross C.A. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995, 378:398-402.
150. Lieberman A.P., Harmison G., Strand A.D., Olson J.M., Fischbeck K.H. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol. Genet. 2002, 11:1967-1976.
151. Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 2001, 8:807-821.
152. Lim J., Crespo-Barreto J., Jafar-Nejad P., Bowman A.B., Richman R., Hill D.E., Orr H.T., Zoghbi H.Y. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452:713-718.
153. Lin J., Handschin C., Spiegelman B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005, 1:361-370.
154. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 2007, 10:1355-1360.
155. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 2000, 48:72-76.
156. Luo D., Renault V.M., Rando T.A. The regulation of Notch signaling in muscle stem cell activation and postnatal myogenesis. Semin. Cell Dev. Biol. 2005, 16:612-622.
157. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan E.Y., Kooperberg C., Krainc D., Young A.B., Tapscott S.J., Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002, 11:1911-1926.
158. Ma T.C., Buescher J.L., Oatis B., Funk J.A., Nash A.J., Carrier R.L., Hoyt K.R. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett. 2007, 411:98-103.
159. Macdonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lin C., Srinidhi L., Barnes G., Taylor S.A., James M., Groot N., Macfarlane H., Jenkins B., Anderson M.A., Wexler N.S., Gusella J.F., Bates G.P., Baxendale S., Hummerich H., Kirby S., North M., Youngman S., Mott R., Zehetner G., Sedlacek Z., Poustka A., Frischauf A.M., Lehrach H., Buckler A.J., Church D., Doucettestamm L., Odonovan M.C., Ribaramirez L., Shah M., Stanton V.P., Strobel S.A., Draths K.M., Wales J.L., Dervan P., Housman D.E., Altherr M., Shiang R., Thompson L., Fielder T., Wasmuth J.J., Tagle D., Valdes J., Elmer L., Allard M., Castilla L., Swaroop M., Blanchard K., Collins F.S., Snell R., Holloway T., Gillespie K., Datson N., Shaw D., Harper P.S. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons-disease chromosomes. Cell 1993, 72:971-983.
160. Malik B., Nirmalananthan N., Bilsland L.G., La Spada A.R., Hanna M.G., Schiavo G., Gallo J.M., Greensmith L. Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2011, 20:1776-1786.
161. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
162. Mariotti C., Castellotti B., Pareyson D., Testa D., Eoli M., Antozzi C., Silani V., Marconi R., Tezzon F., Siciliano G., Marchini C., Gellera C., Donato S.D. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul. Disord. 2000, 10:391-397.
163. Markianos M., Panas M., Kalfakis N., Vassilopoulos D. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann. Neurol. 2005, 57:520-525.
164. Marron T.U., Guerini V., Rusmini P., Sau D., Brevini T.A., Martini L., Poletti A. Androgen-induced neurite outgrowth is mediated by neuritin in motor neurones. J. Neurochem. 2005, 92:10-20.
165. Martin B., Golden E., Carlson O.D., Pistell P., Zhou J., Kim W., Frank B.P., Thomas S., Chadwick W.A., Greig N.H., Bates G.P., Sathasivam K., Bernier M., Maudsley S., Mattson M.P., Egan J.M. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009, 58:318-328.
166. Marzetti E., Lawler J.M., Hiona A., Manini T., Seo A.Y., Leeuwenburgh C. Modulation of age-induced apoptotic signaling and cellular remodeling by exercise and calorie restriction in skeletal muscle. Free Radic. Biol. Med. 2008, 44:160-168.
167. Marzetti E., Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp. Gerontol. 2006, 41:1234-1238.
168. Mauras N., Hayes V., Welch S., Rini A., Helgeson K., Dokler M., Veldhuis J.D., Urban R.J. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J. Clin. Endocrinol. Metab. 1998, 83:1886-1892.
169. Mauro A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 1961, 9:493-495.
170. McGeer E.G., McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976, 263:517-519.
171. McMahon S.J., Pray-Grant M.G., Schieltz D., Yates J.R., Grant P.A. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8478-8482.
172. Mendler L., Baka Z., Kovacs-Simon A., Dux L. Androgens negatively regulate myostatin expression in an androgen-dependent skeletal muscle. Biochem. Biophys. Res. Commun. 2007, 361:237-242.
173. Mihm M.J., Amann D.M., Schanbacher B.L., Altschuld R.A., Bauer J.A., Hoyt K.R. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2007, 25:297-308.
174. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.
175. Milner T.A., Hernandez F.J., Herrick S.P., Pierce J.P., Iadecola C., Drake C.T. Cellular and subcellular localization of androgen receptor immunoreactivity relative to C1 adrenergic neurons in the rostral ventrolateral medulla of male and female rats. Synapse 2007, 61:268-278.
176. Mitsumoto H., Ikeda K., Holmlund T., Greene T., Cedarbaum J.M., Wong V., Lindsay R.M. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. 1994, 36:142-148.
177. Mitsumoto H., Ikeda K., Klinkosz B., Cedarbaum J.M., Wong V., Lindsay R.M. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994, 265:1107-1110.
178. Mo K., Razak Z., Rao P., Yu Z., Adachi H., Katsuno M., Sobue G., Lieberman A.P., Westwood J.T., Monks D.A. Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy. PLoS One 2010, 5:e12922.
179. Moller T. Neuroinflammation in Huntington's disease. J. Neural. Transm. 2010, 117:1001-1008.
180. Monks D.A., Johansen J.A., Mo K., Rao P., Eagleson B., Yu Z., Lieberman A.P., Breedlove S.M., Jordan C.L. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18259-18264.
181. Monks D.A., O'Bryant E.L., Jordan C.L. Androgen receptor immunoreactivity in skeletal muscle: enrichment at the neuromuscular junction. J. Comp. Neurol. 2004, 473:59-72.
182. Montie H.L., Cho M.S., Holder L., Liu Y., Tsvetkov A.S., Finkbeiner S., Merry D.E. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2009, 18:1937-1950.
183. Morfini G., Pigino G., Szebenyi G., You Y., Pollema S., Brady S.T. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat. Neurosci. 2006, 9:907-916.
184. Morton A.J., Leavens W. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res. Bull. 2000, 52:51-59.
185. Moss F.P., Leblond C.P. Satellite cells as the source of nuclei in muscles of growing rats. Anat. Rec. 1971, 170:421-435.
186. Musaro A., Dobrowolny G., Rosenthal N. The neuroprotective effects of a locally acting IGF-1 isoform. Exp. Gerontol. 2007, 42:76-80.
187. Musaro A., McCullagh K., Paul A., Houghton L., Dobrowolny G., Molinaro M., Barton E.R., Sweeney H.L., Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 2001, 27:195-200.
188. Nakamura K., Jeong S.Y., Uchihara T., Anno M., Nagashima K., Nagashima T., Ikeda S., Tsuji S., Kanazawa I. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 2001, 10:1441-1448.
189. Nasir J., Floresco S.B., O'Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., Borowski A., Marth J.D., Phillips A.G., Hayden M.R. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81:811-823.
190. Nedelsky N.B., Pennuto M., Smith R.B., Palazzolo I., Moore J., Nie Z., Neale G., Taylor J.P. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010, 67:936-952.
191. Neff N.T., Prevette D., Houenou L.J., Lewis M.E., Glicksman M.A., Yin Q.W., Oppenheim R.W. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J. Neurobiol. 1993, 24:1578-1588.
192. Neuschmid-Kaspar F., Gast A., Peterziel H., Schneikert J., Muigg A., Ransmayr G., Klocker H., Bartsch G., Cato A.C. CAG-repeat expansion in androgen receptor in Kennedy's disease is not a loss of function mutation. Mol. Cell. Endocrinol. 1996, 117:149-156.
193. Nordeen E.J., Nordeen K.W., Sengelaub D.R., Arnold A.P. Androgens prevent normally occurring cell death in a sexually dimorphic spinal nucleus. Science 1985, 229:671-673.
194. Okamoto K., Hirai S., Ishiguro K., Kawarabayashi T., Takatama M. Light and electron microscopic and immunohistochemical observations of the Onuf's nucleus of amyotrophic lateral sclerosis. Acta Neuropathol. 1991, 81:610-614.
195. Onodera O., Oyake M., Takano H., Ikeuchi T., Igarashi S., Tsuji S. Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS. Am. J. Hum. Genet. 1995, 57:1050-1060.
196. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001, 28:131-138.
197. Ophoff J., Van Proeyen K., Callewaert F., De Gendt K., De Bock K., Vanden Bosch A., Verhoeven G., Hespel P., Vanderschueren D. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 2009, 150:3558-3566.
198. Oppenheim R.W., Houenou L.J., Johnson J.E., Lin L.F., Li L., Lo A.C., Newsome A.L., Prevette D.M., Wang S. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995, 373:344-346.
199. Orr H.T., Chung M.Y., Banfi S., Kwiatkowski T.J., Servadio A., Beaudet A.L., McCall A.E., Duvick L.A., Ranum L.P., Zoghbi H.Y. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 1993, 4:221-226.
200. Orth M., Cooper J.M., Bates G.P., Schapira A.H. Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J. Neurochem. 2003, 87:1-6.
201. Osborne M.C., Verhovshek T., Sengelaub D.R. Androgen regulates trkB immunolabeling in spinal motoneurons. J. Neurosci. Res. 2007, 85:303-309.
202. Ottem E.N., Beck L.A., Jordan C.L., Breedlove S.M. Androgen-dependent regulation of brain-derived neurotrophic factor and tyrosine kinase B in the sexually dimorphic spinal nucleus of the bulbocavernosus. Endocrinology 2007, 148:3655-3665.
203. Oyanagi K., Takeda S., Takahashi H., Ohama E., Ikuta F. A quantitative investigation of the substantia nigra in Huntington's disease. Ann. Neurol. 1989, 26:13-19.
204. Palazzolo I., Burnett B.G., Young J.E., Brenne P.L., La Spada A.R., Fischbeck K.H., Howell B.W., Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum. Mol. Genet. 2007, 16:1593-1603.
205. Palazzolo I., Nedelsky N.B., Askew C.E., Harmison G.G., Kasantsev A.G., Taylor J.P., Fischbeck K.H., Pennuto M. B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. J. Neurosci. Res. 2010, 88:2207-2216.
206. Palazzolo I., Stack C., Kong L., Musaro A., Adachi H., Katsuno M., Sobue G., Taylor J.P., Sumner C.J., Fischbeck K.H., Pennuto M. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009, 63:316-328.
207. Palhan V.B., Chen S., Peng G.H., Tjernberg A., Gamper A.M., Fan Y., Chait B.T., La Spada A.R., Roeder R.G. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8472-8477.
208. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
209. Papalexi E., Persson A., Bjorkqvist M., Petersen A., Woodman B., Bates G.P., Sundler F., Mulder H., Brundin P., Popovic N. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci. 2005, 22:1541-1546.
210. Paradisi I., Hernandez A., Arias S. Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation. J. Hum. Genet. 2008, 53:127-135.
211. Pattison J.S., Sanbe A., Maloyan A., Osinska H., Klevitsky R., Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 2008, 117:2743-2751.
212. Paulson H.L., Das S.S., Crino P.B., Perez M.K., Patel S.C., Gotsdiner D., Fischbeck K.H., Pittman R.N. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 1997, 41:453-462.
213. Pennuto M., Palazzolo I., Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum. Mol. Genet. 2009, 18:R40-R47.
214. Peters M.F., Nucifora F.C., Kushi J., Seaman H.C., Cooper J.K., Herring W.J., Dawson V.L., Dawson T.M., Ross C.A. Nuclear targeting of mutant Huntingtin increases toxicity. Mol. Cell. Neurosci. 1999, 14:121-128.
215. Petersen A., Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci. 2006, 24:961-967.
216. Petersen A., Gil J., Maat-Schieman M.L., Bjorkqvist M., Tanila H., Araujo I.M., Smith R., Popovic N., Wierup N., Norlen P., Li J.Y., Roos R.A., Sundler F., Mulder H., Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Genet. 2005, 14:39-47.
217. Phan J., Hickey M.A., Zhang P., Chesselet M.F., Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 2009, 18:1006-1016.
218. Podolsky S., Leopold N.A. Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 1977, 23:55-63.
219. Podolsky S., Leopold N.A., Sax D.S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972, 1:1356-1358.
220. Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front. Neuroendocrinol. 2004, 25:1-26.
221. Popovic V., Svetel M., Djurovic M., Petrovic S., Doknic M., Pekic S., Miljic D., Milic N., Glodic J., Dieguez C., Casanueva F.F., Kostic V. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur. J. Endocrinol. 2004, 151:451-455.
222. Rao A.K., Muratori L., Louis E.D., Moskowitz C.B., Marder K.S. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov. Disord. 2008, 23:1100-1107.
223. Ribchester R.R., Thomson D., Wood N.I., Hinks T., Gillingwater T.H., Wishart T.M., Court F.A., Morton A.J. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. 2004, 20:3092-3114.
224. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., Yancopoulos G.D., Glass D.J. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3:1009-1013.
225. Roselli C.E., Handa R.J., Resko J.A. Quantitative distribution of nuclear androgen receptors in microdissected areas of the rat brain. Neuroendocrinology 1989, 49:449-453.
226. Runne H., Regulier E., Kuhn A., Zala D., Gokce O., Perrin V., Sick B., Aebischer P., Deglon N., Luthi-Carter R. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J. Neurosci. 2008, 28:9723-9731.
227. Rusmini P., Bolzoni E., Crippa V., Onesto E., Sau D., Galbiati M., Piccolella M., Poletti A. Proteasomal and autophagic degradative activities in spinal and bulbar muscular atrophy. Neurobiol. Dis. 2010, 40:361-369.
228. Sakuma K., Yamaguchi A. Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr. Aging Sci. 2010, 3:90-101.
229. Salazar-Grueso E.F., Kim S., Kim H. Embryonic mouse spinal cord motor neuron hybrid cells. Neuroreport 1991, 2:505-508.
230. Sanberg P.R., Fibiger H.C., Mark R.F. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust. 1981, 1:407-409.
231. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S.H., Goldberg A.L. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
232. Sapp E., Kegel K.B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P.G., Vonsattel J.P., DiFiglia M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60:161-172.
233. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
234. Schmidt B.J., Greenberg C.R., Allingham-Hawkins D.J., Spriggs E.L. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002, 59:770-772.
235. Schmidt T., Landwehrmeyer G.B., Schmitt I., Trottier Y., Auburger G., Laccone F., Klockgether T., Volpel M., Epplen J.T., Schols L., Riess O. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998, 8:669-679.
236. Sendtner M., Holtmann B., Kolbeck R., Thoenen H., Barde Y.A. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature 1992, 360:757-759.
237. Sengelaub D.R., Forger N.G. The spinal nucleus of the bulbocavernosus: firsts in androgen-dependent neural sex differences. Horm. Behav. 2008, 53:596-612.
238. Servadio A., Koshy B., Armstrong D., Antalffy B., Orr H.T., Zoghbi H.Y. Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals. Nat. Genet. 1995, 10:94-98.
239. Sharpe R.M., Fraser H.M., Ratnasooriya W.D. Assessment of the role of Leydig cell products other than testosterone in spermatogenesis and fertility in adult rats. Int. J. Androl. 1988, 11:507-523.
240. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 2005, 171:1001-1012.
241. Simerly R.B., Chang C., Muramatsu M., Swanson L.W. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. J. Comp. Neurol. 1990, 294:76-95.
242. Simmons D.A., Casale M., Alcon B., Pham N., Narayan N., Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007, 55:1074-1084.
243. Sinha-Hikim I., Artaza J., Woodhouse L., Gonzalez-Cadavid N., Singh A.B., Lee M.I., Storer T.W., Casaburi R., Shen R., Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E154-E164.
244. Sinha-Hikim I., Cornford M., Gaytan H., Lee M.L., Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J. Clin. Endocrinol. Metab. 2006, 91:3024-3033.
245. Sinha-Hikim I., Roth S.M., Lee M.I., Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E197-E205.
246. Sinha-Hikim I., Taylor W.E., Gonzalez-Cadavid N.F., Zheng W., Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J. Clin. Endocrinol. Metab. 2004, 89:5245-5255.
247. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., Davies P., MacDonald M.E., Gusella J.F., Harper P.S., Shaw D.J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 1993, 4:393-397.
248. Sobue G. X-linked recessive bulbospinal neuronopathy (SBMA). Nagoya J. Med. Sci. 1995, 58:95-106.
249. Sopher B.L., Thomas P.S., LaFevre-Bernt M.A., Holm I.E., Wilke S.A., Ware C.B., Jin L.W., Libby R.T., Ellerby L.M., La Spada A.R. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 2004, 41:687-699.
250. Soraru G., D'Ascenzo C., Polo A., Palmieri A., Baggio L., Vergani L., Gellera C., Moretto G., Pegoraro E., Angelini C. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J. Neurol. Sci. 2008, 264:100-105.
251. Sorenson E.J., Klein C.J. Elevated creatine kinase and transaminases in asymptomatic SBMA. Amyotroph. Lateral Scler. 2007, 8:62-64.
252. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., Gonzalez M., Yancopoulos G.D., Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 2004, 14:395-403.
253. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.P., Appelmans S., Oh H., Van Damme P., Rutten B., Man W.Y., De Mol M., Wyns S., Manka D., Vermeulen K., Van Den Bosch L., Mertens N., Schmitz C., Robberecht W., Conway E.M., Collen D., Moons L., Carmeliet P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 2005, 8:85-92.
254. Stoy N., McKay E. Weight loss in Huntington's disease. Ann. Neurol. 2000, 48:130-131.
255. Strand A.D., Aragaki A.K., Shaw D., Bird T., Holton J., Turner C., Tapscott S.J., Tabrizi S.J., Schapira A.H., Kooperberg C., Olson J.M. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum. Mol. Genet. 2005, 14:1863-1876.
256. Strong T.V., Tagle D.A., Valdes J.M., Elmer L.W., Boehm K., Swaroop M., Kaatz K.W., Collins F.S., Albin R.L. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Genet. 1993, 5:259-265.
257. Suzuki M., Desmond T.J., Albin R.L., Frey K.A. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse 2001, 41:329-336.
258. Szebenyi G., Morfini G.A., Babcock A., Gould M., Selkoe K., Stenoien D.L., Young M., Faber P.W., MacDonald M.E., McPhaul M.J., Brady S.T. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 2003, 40:41-52.
259. Tabori N.E., Stewart L.S., Znamensky V., Romeo R.D., Alves S.E., McEwen B.S., Milner T.A. Ultrastructural evidence that androgen receptors are located at extranuclear sites in the rat hippocampal formation. Neuroscience 2005, 130:151-163.
260. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007, 130:1759-1766.
261. Takeyama K., Ito S., Yamamoto A., Tanimoto H., Furutani T., Kanuka H., Miura M., Tabata T., Kato S. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002, 35:855-864.
262. Tan S.A., Deglon N., Zurn A.D., Baetge E.E., Bamber B., Kato A.C., Aebischer P. Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Cell Transplant. 1996, 5:577-587.
263. Tetzlaff J., Tanzer L., Jones K.J. Cellular localization of androgen and estrogen receptors in mouse-derived motoneuron hybrid cells and mouse facial motoneurons. Dev. Neurobiol. 2007, 67:1362-1370.
264. Thomas E.A., Coppola G., Tang B., Kuhn A., Kim S., Geschwind D.H., Brown T.B., Luthi-Carter R., Ehrlich M.E. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum. Mol. Genet. 2011, 20:1049-1060.
265. Thomas P.S., Fraley G.S., Damian V., Woodke L.B., Zapata F., Sopher B.L., Plymate S.R., La Spada A.R. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2006, 15:2225-2238.
266. Thompson P.D., Berardelli A., Rothwell J.C., Day B.L., Dick J.P., Benecke R., Marsden C.D. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1988, 111(Pt 2):223-244.
267. Timmers H.J., Swaab D.F., van de Nes J.A., Kremer H.P. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. Brain Res. 1996, 728:141-148.
268. Trejo J.L., Carro E., Garcia-Galloway E., Torres-Aleman I. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J. Mol. Med. 2004, 82:156-162.
269. Trushina E., Dyer R.B., Badger J.D., Ure D., Eide L., Tran D.D., Vrieze B.T., Legendre-Guillemin V., McPherson P.S., Mandavilli B.S., Van Houten B., Zeitlin S., McNiven M., Aebersold R., Hayden M., Parisi J.E., Seeberg E., Dragatsis I., Doyle K., Bender A., Chacko C., McMurray C.T. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 2004, 24:8195-8209.
270. Tsai M.Y., Yeh S.D., Wang R.S., Yeh S., Zhang C., Lin H.Y., Tzeng C.R., Chang C. Differential effects of spermatogenesis and fertility in mice lacking androgen receptor in individual testis cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18975-18980.
271. Van Den Bosch L., Storkebaum E., Vleminckx V., Moons L., Vanopdenbosch L., Scheveneels W., Carmeliet P., Robberecht W. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol. Dis. 2004, 17:21-28.
272. van der Burg J.M., Bacos K., Wood N.I., Lindqvist A., Wierup N., Woodman B., Wamsteeker J.I., Smith R., Deierborg T., Kuhar M.J., Bates G.P., Mulder H., Erlanson-Albertsson C., Morton A.J., Brundin P., Petersen A., Bjorkqvist M. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2008, 29:41-51.
273. Van Raamsdonk J.M., Gibson W.T., Pearson J., Murphy Z., Lu G., Leavitt B.R., Hayden M.R. Body weight is modulated by levels of full-length huntingtin. Hum. Mol. Genet. 2006, 15:1513-1523.
274. Van Raamsdonk J.M., Murphy Z., Selva D.M., Hamidizadeh R., Pearson J., Petersen A., Bjorkqvist M., Muir C., Mackenzie I.R., Hammond G.L., Vogl A.W., Hayden M.R., Leavitt B.R. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007, 26:512-520.
275. Van Raamsdonk J.M., Warby S.C., Hayden M.R. Selective degeneration in YAC mouse models of Huntington disease. Brain Res. Bull. 2007, 72:124-131.
276. Verhovshek T., Cai Y., Osborne M.C., Sengelaub D.R. Androgen regulates brain-derived neurotrophic factor in spinal motoneurons and their target musculature. Endocrinology 2010, 151:253-261.
277. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
278. Vornberger W., Prins G., Musto N.A., Suarez-Quian C.A. Androgen receptor distribution in rat testis: new implications for androgen regulation of spermatogenesis. Endocrinology 1994, 134:2307-2316.
279. Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P.J., Cunningham G., Matsumoto A.M., Weber T., Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 2000, 85:2839-2853.
280. Ward O.B., Wexler A.M., Carlucci J.R., Eckert M.A., Ward I.L. Critical periods of sensitivity of sexually dimorphic spinal nuclei to prenatal testosterone exposure in female rats. Horm. Behav. 1996, 30:407-415.
281. Warrick J.M., Morabito L.M., Bilen J., Gordesky-Gold B., Faust L.Z., Paulson H.L., Bonini N.M. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell. 2005, 18:37-48.
282. Watson N.V., Freeman L.M., Breedlove S.M. Neuronal size in the spinal nucleus of the bulbocavernosus: direct modulation by androgen in rats with mosaic androgen insensitivity. J. Neurosci. 2001, 21:1062-1066.
283. Weydt P., Pineda V.V., Torrence A.E., Libby R.T., Satterfield T.F., Lazarowski E.R., Gilbert M.L., Morton G.J., Bammler T.K., Strand A.D., Cui L., Beyer R.P., Easley C.N., Smith A.C., Krainc D., Luquet S., Sweet I.R., Schwartz M.W., La Spada A.R. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006, 4:349-362.
284. Wolf R.C., Sambataro F., Vasic N., Schonfeldt-Lecuona C., Ecker D., Landwehrmeyer B. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Exp. Neurol. 2008, 213:137-144.
285. Wolf R.C., Sambataro F., Vasic N., Schonfeldt-Lecuona C., Ecker D., Landwehrmeyer B. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load. Eur. J. Neurol. 2008, 15:1180-1190.
286. Wolf R.C., Sambataro F., Vasic N., Wolf N.D., Thomann P.A., Landwehrmeyer G.B., Orth M. Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Exp. Neurol. 2011, 231:214-222.
287. Wolf R.C., Vasic N., Schonfeldt-Lecuona C., Landwehrmeyer G.B., Ecker D. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 2007, 130:2845-2857.
288. Xiang Z., Valenza M., Cui L., Leoni V., Jeong H.K., Brilli E., Zhang J., Peng Q., Duan W., Reeves S.A., Cattaneo E., Krainc D. Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. J. Neurosci. 2011, 31:9544-9553.
289. Xu J., Gingras K.M., Bengston L., Di Marco A., Forger N.G. Blockade of endogenous neurotrophic factors prevents the androgenic rescue of rat spinal motoneurons. J. Neurosci. 2001, 21:4366-4372.
290. Xu Q., Lin H.Y., Yeh S.D., Yu I.C., Wang R.S., Chen Y.T., Zhang C., Altuwaijri S., Chen L.M., Chuang K.H., Chiang H.S., Yeh S., Chang C. Infertility with defective spermatogenesis and steroidogenesis in male mice lacking androgen receptor in Leydig cells. Endocrine 2007, 32:96-106.
291. Yamamoto M., Mitsuma N., Inukai A., Ito Y., Li M., Mitsuma T., Sobue G. Expression of GDNF and GDNFR-alpha mRNAs in muscles of patients with motor neuron diseases. Neurochem. Res. 1999, 24:785-790.
292. Yan Q., Matheson C., Lopez O.T. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995, 373:341-344.
293. Yang L.Y., Verhovshek T., Sengelaub D.R. Brain-derived neurotrophic factor and androgen interact in the maintenance of dendritic morphology in a sexually dimorphic rat spinal nucleus. Endocrinology 2004, 145:161-168.
294. Yeh S., Tsai M.Y., Xu Q., Mu X.M., Lardy H., Huang K.E., Lin H., Yeh S.D., Altuwaijri S., Zhou X., Xing L., Boyce B.F., Hung M.C., Zhang S., Gan L., Chang C. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13498-13503.
295. Yohrling G.J., Jiang G.C., DeJohn M.M., Miller D.W., Young A.B., Vrana K.E., Cha J.H. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Brain Res. Mol. Brain Res. 2003, 119:28-36.
296. Yu Z., Dadgar N., Albertelli M., Gruis K., Jordan C., Robins D.M., Lieberman A.P. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J. Clin. Invest. 2006, 116:2663-2672.
297. Yu Z., Dadgar N., Albertelli M., Scheller A., Albin R.L., Robins D.M., Lieberman A.P. Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am. J. Pathol. 2006, 168:195-204.
298. Yu Z., Wang A.M., Adachi H., Katsuno M., Sobue G., Yue Z., Robins D.M., Lieberman A.P. Macroautophagy is regulated by the UPR-Mediator CHOP and Accentuates the Phenotype of SBMA Mice. PLoS Genet. 2011, 7:e1002321.
299. Yu Z., Wang A.M., Robins D.M., Lieberman A.P. Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice. Dis. Model. Mech. 2009, 2:500-507.
300. Yvert G., Lindenberg K.S., Picaud S., Landwehrmeyer G.B., Sahel J.A., Mandel J.L. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum. Mol. Genet. 2000, 9:2491-2506.
301. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 1995, 11:155-163.
302. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
303. Zhang C., Yeh S., Chen Y.T., Wu C.C., Chuang K.H., Lin H.Y., Wang R.S., Chang Y.J., Mendis-Handagama C., Hu L., Lardy H., Chang C. Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17718-17723.
304. Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., Lecker S.H., Goldberg A.L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007, 6:472-483.
305. Zhong X., Pittman R.N. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates. Hum. Mol. Genet. 2006, 15:2409-2420.
306. Zhuchenko O., Bailey J., Bonnen P., Ashizawa T., Stockton D.W., Amos C., Dobyns W.B., Subramony S.H., Zoghbi H.Y., Lee C.C. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 1997, 15:62-69.
307. Zimbelman J.L., Paulsen J.S., Mikos A., Reynolds N.C., Hoffmann R.G., Rao S.M. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J. Int. Neuropsychol. Soc. 2007, 13:758-769.
308. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B.R., Hayden M.R., Timmusk T., Rigamonti D., Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
309. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.
310. Zurn A.D., Baetge E.E., Hammang J.P., Tan S.A., Aebischer P. Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurones. Neuroreport 1994, 6:113-118.